Filing Details

Accession Number:
0001127602-17-009851
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-03-02 17:57:54
Reporting Period:
2017-03-01
Filing Date:
2017-03-02
Accepted Time:
2017-03-02 17:57:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1520262 Alkermes Plc. ALKS Pharmaceutical Preparations (2834) 981007018
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1524823 Shane Cooke Connaught House
1 Burlington Road
Dublin 4 Ireland
President, Alkermes Plc No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2017-03-01 7,000 $0.00 73,068 No 4 M Direct
Ordinary Shares Disposition 2017-03-01 3,640 $59.71 69,428 No 4 F Direct
Ordinary Shares Acquisiton 2017-03-02 20,000 $14.60 89,428 No 4 M Direct
Ordinary Shares Disposition 2017-03-02 20,000 $60.00 69,428 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Restricted Stock Unit Award Disposition 2017-03-01 7,000 $0.00 7,000 $0.00
Ordinary Shares Employee Stock Option (Right to Buy) Disposition 2017-03-02 20,000 $0.00 20,000 $14.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
21,000 2017-03-01 No 4 M Direct
4,000 2021-10-05 No 4 M Direct
Footnotes
  1. This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  3. Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017.
  4. These options are fully vested in accordance with their terms.